The pharmaceutical industry is well past the time when licensing was seen as merely a supplement to the internal R&D program. Now, it often plays a more important role than the company's internal R&D. As dealmaking becomes a bigger part of the overall pipeline building program, investors will require greater clarity from companies who now can bury external dealmaking costs in one-time write-offs or aggregated clash flow numbers.
by Roger Longman
The industry is now well past the time when licensing was a corporate backstop, seen as a mere supplement to...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.
MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.
